LGR۵ As A Potential Therapeutic Target for Breas tCancer: A Sys tematic Review and Meta-Analysis
- سال انتشار: 1401
- محل انتشار: بیست و سومین کنگره بین المللی هیبریدی پزشکی تولید مثل و هجدهمین کنگره هیبریدی فناوری سلولهای بنیادی رویان
- کد COI اختصاصی: RROYAN23_286
- زبان مقاله: انگلیسی
- تعداد مشاهده: 133
نویسندگان
Gas trointes tinal Cancer Research Center, Non-communicableDiseases Ins titute, Mazandaran University of Medical Sciences,Sari, Iran
Gas trointes tinal Cancer Research Center, Non-communicableDiseases Ins titute, Mazandaran University of Medical Sciences,Sari, Iran
Gas trointes tinal Cancer Research Center, Non-communicableDiseases Ins titute, Mazandaran University of Medical Sciences,Sari, Iran
Kazakh Research Ins titute of Oncology and Radiology, Kazakhstan, Kazakh Research Ins titute of Oncology and Radiology, Kazakhstan, Almaty, Kazakhs tan
چکیده
Objective: Since the emergence of precision medicine, the developmentof cancer s tem cells (CSCs) has promoted the implementationof novel patient-centered therapies. Leucine-richrepeat-containing G-protein-coupled receptor ۵ (LGR۵), theso-called GPR۴۹, plays a considerable role in the heterogeneityof tumors such as breas t cancer. Breas t cancer has emerged asthe mos t common malignancy worldwide as of ۲۰۲۱. The implicationof LGR۵ in novel approaches to breas t cancer therapyis a potential landscape for research. We aimed to assess theprevalence, prognos tic, and therapeutic role of LGR۵ in breas tcancer.Materials and Methods: We performed this sys tematic reviewand meta-analysis s tudy using databases including Web of Science,Scopus, and PubMed. We searched these databases usingLGR۵ and Breas t Cancer and related keywords based on theMeSH database until October ۱۲, ۲۰۲۱. All s tudies that reportedthe prevalence of LGR۵ overexpression via Immunohis tochemistry (IHC) in breas t cancer patients were included in thisreview. We applied the S tATA and random effect models fordata analysis.Results: Finally, seven s tudies of ۲۶۳۲ breas t cancer sampleswere reviewed in this s tudy. The pooled prevalence ofLGR۵ high expression in breas t cancer was ۳۶ % (۹۵%CI:۲۶-۴۷.۵%, I۲= ۹۵.۵) and in triple-negative breas t cancer was۴۸.۶% (۹۵%CI: ۳۸.۴-۵۸.۷%, I۲= ۰.۰). There was a s tatis ticalsignificance in the correlation between LGR۵ overexpressionand ER+ breas t cancer patients (pooled OR: ۰.۵۴, ۹۵%CI: ۰.۳۲-۰.۹۲, I۲: ۶۲%). Furthermore, we observed that LGR۵ overexpressionis correlated with TNM s taging of tumors (pooled OR:۵.۰۶, ۹۵%CI: ۲.۶۳-۹.۷۴).Conclusion: In principle, the prevalence of LGR۵ high expressionin breas t cancer particularly triple-negative types wasconsiderable. Hence, we sugges t that LGR۵ can be a potentialtherapeutic target for breas t cancer. The effectiveness of LGR۵in the tailored treatment of breas t cancer needs further inves tigation.کلیدواژه ها
Breas t Cancer, Cancer S tem Cell, Leucine-Rich Repeat-Containing G-Protein-Coupled Receptor ۵ (LGR۵), TailoredMedicineاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.